Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results

BACKGROUND: Twelve months treatment is the current standard of care for adjuvant trastuzumab in patients with HER2 positive early breast cancer however the optimal duration is not known. Persephone is a non-inferiority randomised controlled trial comparing 6- to 12-months of trastuzumab. In this tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Hiller, Louise, Dunn, Janet A., Loi, Shrushma, Vallier, Anne-Laure, Howe, Donna L., Cameron, David A., Miles, David, Wardley, Andrew M., Earl, Helena M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887251/
https://www.ncbi.nlm.nih.gov/pubmed/29621991
http://dx.doi.org/10.1186/s12885-018-4307-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887251/
https://www.ncbi.nlm.nih.gov/pubmed/29621991
http://dx.doi.org/10.1186/s12885-018-4307-8

Ejemplares similares